-transparent.png){kind=logo}
To establish whether nitric-oxide (NO) participates in the regulation of prolactin (PRL) secretion in humans in basal conditions and/or under stimulation with vasoactive intestinal polypeptide (VIP), seven normal men were treated with a placebo (normal saline) or the NO synthase (NOS) inhibitor L-NAME (40 microg/kg injected plus 50 microg/kg infused intravenously over 60 minutes), which in previous studies has been found able to modify other pituitary hormone secretions. Experiments were performed either in basal conditions or during stimulation of PRL secretion with an intravenous infusion of VIP (4 pmol/kg min over 60 minutes). The administration of L-NAME was unable to change the basal secretion of PRL. In contrast, L-NAME significantly enhanced the PRL increase induced by VIP. These data argue against an involvement of NO in regulation of basal PRL secretion. In contrast, the stimulatory effect of L-NAME on VIP-induced PRL secretion suggests that NO exerts an inhibitory control of the PRL response to VIP.
P Chiodera, and
R Volpi, and
V Coiro
August 1987,
Geburtshilfe und Frauenheilkunde,
P Chiodera, and
R Volpi, and
V Coiro
January 1988,
Endocrinology,
P Chiodera, and
R Volpi, and
V Coiro
February 1981,
Comptes rendus des seances de l'Academie des sciences. Serie III, Sciences de la vie,
P Chiodera, and
R Volpi, and
V Coiro
November 1989,
Neuroendocrinology,
P Chiodera, and
R Volpi, and
V Coiro
June 1980,
American journal of surgery,
P Chiodera, and
R Volpi, and
V Coiro
July 1996,
Experimental eye research,
P Chiodera, and
R Volpi, and
V Coiro
December 1998,
Annals of the New York Academy of Sciences,
P Chiodera, and
R Volpi, and
V Coiro
June 1980,
American journal of surgery,
P Chiodera, and
R Volpi, and
V Coiro
February 1996,
Endocrinology,
P Chiodera, and
R Volpi, and
V Coiro
August 2006,
Journal of applied physiology (Bethesda, Md. : 1985),
